KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Net Margin (2018 - 2025)

Vir Biotechnology's Net Margin history spans 8 years, with the latest figure at 66.99% for Q4 2025.

  • For Q4 2025, Net Margin rose 77824.0% year-over-year to 66.99%; the TTM value through Dec 2025 reached 638.87%, up 11183.0%, while the annual FY2025 figure was 638.87%, 6453.0% up from the prior year.
  • Net Margin for Q4 2025 was 66.99% at Vir Biotechnology, up from 67975.42% in the prior quarter.
  • Across five years, Net Margin topped out at 106.57% in Q3 2021 and bottomed at 67975.42% in Q3 2025.
  • The 5-year median for Net Margin is 457.33% (2023), against an average of 5825.31%.
  • The largest annual shift saw Net Margin surged 859021bps in 2022 before it plummeted -5899571bps in 2025.
  • A 5-year view of Net Margin shows it stood at 63.94% in 2021, then plummeted by -422bps to 205.63% in 2022, then tumbled by -236bps to 690.85% in 2023, then fell by -22bps to 845.23% in 2024, then surged by 92bps to 66.99% in 2025.
  • Per Business Quant, the three most recent readings for VIR's Net Margin are 66.99% (Q4 2025), 67975.42% (Q3 2025), and 9139.87% (Q2 2025).